The Department of Health and Human Services late Thursday announced that Gilead, the drug company behind the pre-exposure prophylaxis (PrEP) medication medication Truvada, would provide PrEP for up to 200,000 individuals each year for up to 11 years, reports Towleroad.
HHS writes: The agreement between the U.S. Department of Health and Human Services and Gilead will last until at least December 31, 2025 and possibly through December 31, 2030, and will provide medication to treat individuals who are at risk for HIV and who are uninsured. This donation will deliver Gilead’s PrEP medication Truvada, which currently carries a list price of more than $20,000 per patient per year, to up to 200,000 people per year, including in the states and counties identified as priority areas … to end the HIV epidemic in America.”
READ MORE HERE:
